Rituximab and milatuzumab combination treatment inhibited nuclear total p65 translocation in MCL cell lines. Top panels show nuclear and cytosolic protein fractions collected at 4 hours prepared from Jeko (A) and Mino (B) cell lines and subjected to immunoblot analysis for p65, α-tubulin (cytoplasmic control), and Brg-1 (nuclear control). Bottom panels show confocal microscopic analysis of intracellular localization of total p65 (green) in Jeko (A) and Mino (B) cells. MCL cells were treated with cross-linking antibody, trastuzumab, rituximab, milatuzumab, and the combination of rituximab and milatuzumab in the presence of a cross-linking antibody. After 4 hours, cells were collected and prepared for confocal microscopy analysis. DRAQ5 was used for nuclear staining.